Ferramentas para avaliação e acompanhamento da urticária crônica
Patient-reported outcomes for the evaluation and follow-up of chronic urticaria
Solange Oliveira Rodrigues Valle; Sérgio Duarte Dortas-Junior; Gabriela Andrade Coelho Dias; Antônio Abílio Motta; Claudia Soïdo Falcão do-Amaral; Emmanuel Antonio P. Reis Martins; Luis Felipe Chiaverini Ensina; Márcia Carvalho Mallozi; Maria das Graças de Melo Teixeira Spengler; Maria Fernanda Ferraro; Mário Cezar Pires; Maurício Martins; Nelson Guilherme Bastos Cordeiro; Regis de Albuquerque Campos; Rosana Câmara Agondi Leite; Alfeu Tavares França
Resumo
Urticária é uma doença pruriginosa da pele na qual ocorrem urticas e/ou angioedema. A urticária é definida como crônica quando persiste por 6 semanas ou mais. A urticária crônica tem um grande impacto na vida diária do paciente. Atualmente, não há biomarcadores confiáveis para identificar e medir a atividade da doença na urticária crônica espontânea. Consequentemente, o uso de ferramentas conhecidas por patient-reported outcomes (PROs) é crucial ao avaliar e monitorar diferentes aspectos da urticária crônica, como atividade/gravidade da doença, controle da doença e qualidade de vida. Apresentamos uma visão geral de cinco PROs usados na avaliação da urticária crônica, e destacamos suas vantagens, limitações e uso na prática clínica e pesquisa.
Palavras-chave
Abstract
Urticaria is an itching skin disease characterized by the presence of wheals and/or angioedema. Urticaria is defined as chronic when it persists for 6 weeks or more. Chronic urticaria has great impact on the daily lives of patients. Currently, there are no reliable biomarkers to identify and measure disease activity in chronic spontaneous urticaria. Consequently, the use of tools known as patient-reported outcomes (PROs) is crucial when evaluating and monitoring different aspects of chronic urticaria such as disease activity/severity, disease control, and quality of life. We present an overview of the five PROs used in the evaluation of chronic urticaria, highlighting their advantages, limitations, and use in clinical practice and research.
Keywords
References
1. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, BallmerWeber B, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018 Jul;73(7):1393‑414.
2. Maurer M, Weller K, Bindslev-Jensen C et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011;66:317‑30.
3. Gimenez-Arnau AM, Grattan C, Zuberbier T, Toubi E. An individualized diagnostic approach based on guidelines for chronic urticaria (CU). J Eur Acad Dermatol Venereol. 2015;29(Suppl 3):3-11.
4. Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GALEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780-802.
5. O’ Donnell BF. Impact on Quality of Life and Economic Cost. Immunol Allergy Clin N Am. 2014;34:89-104.
6. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997 Feb;136(2):197-201.
7. Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, et al. Quality of life and patients´ satisfaction in chronic urticaria and respiratory allergy. Allergy. 2003 Jul;58(7):621-3.
8. Grob JJ, Guady-Marqueste C. Urticaria and quality of life. Clin Rev Allergy Immunol. 2006 Feb;30(1):47-51.
9. Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, et al. Recommendations for assessing patientreported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy. 2011;66(7):840-4.
10. Moestrup K, Ghazanfar MN, Thomsen SF. Patient-reported outcomes (PROs) in chronic urticaria. Int J Dermatol. 2017 Jun 1. doi: 10.1111/ ijd.13668. [Epub ahead of print] Review.
11. Patrick DL. A qualidade de vida pode ser medida? Como? In: Fleck MPA. A avaliação de qualidade de vida: guia para profissionais da saúde. Ed. Artmed; 2008. p. 29-39.
12. Zuberbier T. Urticaria. Allergy. 2003;58:1224-34.
13. Jáuregui I, Ortiz de Frutos FJ, Ferrer M, Giménez-Arnau A, Sastre J, Bartra J, et al. Assessment of severity and quality of life in chronic urticaria. J Investig Allergol Clin Immunol. 2014;24(2):80-6.
14. Weller K, Church MK, Kalogeromitros D, Krause K, Magerl M, Metz M, et al. Chronic spontaneous urticaria: how to assess quality of life in patients receiving treatment. Arch Dermatol. 2011;147:1221-3.
15. Weller K, Zuberbier T, Maurer M. Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. Curr Opin Allergy Clin Immunol. 2015;15:220‑6.
16. Stull D, McBride D, Tian H, Gimenez Arnau A, Maurer M, Marsland A,et al. Analysis of Disease Activity Categories in Chronic Spontaneous/Idiopathic Urticaria. Br J Dermatol. 2017 Mar 13. doi: 10.1111/bjd.15454. [Epub ahead of print] PubMed PMID: 28295198.
17. Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patientreported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133:1365-72.
18. Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60:1073-8.
19. Kulthanan K, Chularojanamontri L, Tuchinda P, Rujitharanawong C, Baiardini I, Braido F. Minimal clinical important difference (MCID) of the Thai Chronic Urticaria Quality of Life Questionnaire (CUQ2oL). Asian Pac J Allergy Immunol. 2016;34:137-45.
20. Weller K, Siebenhaar F, Hawro T, Altrichter S, Schoepke N, Maurer M. Clinical Measures of Chronic Urticaria. Immunol Allergy Clin North Am. 2017 Feb;37(1):35-49.
21. Ohanyan T, Schoepke N, Bolukbasi B, Metz M, Hawro T, Zuberbier T, et al. Responsiveness and minimal important difference of the urticaria control test. J Allergy Clin Immunol. 2017 Jun 16. pii: S0091-6749(17)30992-2.
22. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development, validation, and initial results of the Angioedema Activity Score. Allergy. 2013 Sep;68(9):1185-92.
23. Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012 Oct;67(10):1289-98.
24. Maurer M, Church MK, Marsland AM, Sussman G, Siebenhaar F, Vestergaard C, et al. Questions and answers in chronic urticaria: where do we stand and where do we go? J Eur Acad Dermatol Venereol. 2016 Jul;30 Suppl 5:7-15.
25. Maurer M, Metz M, Bindslev-Jensen C, Bousquet J, Canonica GW, Church MK, et al. Definition, aims, and implementation of GA(2) LEN Urticaria Centers of Reference and Excellence. Allergy. 2016 Aug;71(8):1210-8.
Submitted date:
12/28/2017
Accepted date:
03/10/2018
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email